## I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims**

3 .

Claim 1-44. (Cancelled)

Claim 45. (New) A method of treating an inflammatory process and minimizing gastrointestinal side-effects comprising:

- (a) arranging seven capsules containing an active agent consisting essentially of 15 mg lansoprazole per capsule and fourteen tablets containing an active agent consisting essentially of 500 mg naproxen per tablet into a blister package comprising:
  - (i) a first set of seven rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said lansoprazole capsules;
  - (ii) a second set seven rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said naproxen tablets; and
  - (iii) a third set seven rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said naproxen tablets;
- (b) rupturing one or more substrates to dispense one or more unit doses from the drug packaging system; and
- (c) administering one lansoprazole capsule daily and one naproxen tablet twice daily to a human patient.